Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDRT + SBRT followed by Iparomlimab + Tuvonralimab as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2600125500Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab and tuvonralimab in head and neck squamous cell carcinoma (HNSCC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Pathologic Complete Response. Planned start May 2026; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600125500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125500.